Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan W Carter

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Diabetes Technology & Therapeutics|November 27, 2002
Home fructosamine testing: is its demise premature?Alan W Carter
Journal of Diabetes Science and Technology|August 31, 2014
FDA-approved biosimilar insulin: good enough for critical care, adulterated, or counterfeit? How can we tell?Alan W Carter
Journal of Diabetes Science and Technology|February 10, 2011
Analysis of the injection force of solostar® compared with other disposable insulin pen devices at constant volume flow ratesAlan W Carter
Journal of Diabetes Science and Technology|November 4, 2009
An analysis of the assessment of glycated hemoglobin using A1cNow+ point-of-care device compared to central laboratory testing--an important addition to pharmacist-managed diabetes programs?Alan W Carter
Journal of Diabetes Science and Technology|January 29, 2016
In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin?Alan W Carter
Journal of Diabetes Science and Technology|July 7, 2016
If PBMs Guard Access to Drugs, Then Quis Custodiet Ipsos Custodies? (Who Will Guard the Guardians?)Alan W Carter, Lutz Heinemann
Journal of Diabetes Science and Technology|December 23, 2017
Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply ChainAlan W Carter, Lutz Heinemann
Journal of Diabetes Science and Technology|May 24, 2018
In Response to Letters to the Editor From the American Diabetes Association and Eli Lilly in Regard to: Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply ChainAlan W Carter, Lutz Heinemann
Diabetes Technology & Therapeutics|September 9, 2017
Will Biosimilar Insulins Be Cheaper?Lutz Heinemann, Alan W Carter
Journal of Diabetes Science and Technology|March 19, 2016
Quality Control of Insulins and Biosimilar Insulins: What Do We Know?Alan W Carter, Lutz Heinemann, David C Klonoff, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Diabetes Technology & Therapeutics|November 27, 2002
Home fructosamine testing: is its demise premature?Alan W Carter
Journal of Diabetes Science and Technology|August 31, 2014
FDA-approved biosimilar insulin: good enough for critical care, adulterated, or counterfeit? How can we tell?Alan W Carter
Journal of Diabetes Science and Technology|February 10, 2011
Analysis of the injection force of solostar® compared with other disposable insulin pen devices at constant volume flow ratesAlan W Carter
Journal of Diabetes Science and Technology|November 4, 2009
An analysis of the assessment of glycated hemoglobin using A1cNow+ point-of-care device compared to central laboratory testing--an important addition to pharmacist-managed diabetes programs?Alan W Carter
Journal of Diabetes Science and Technology|January 29, 2016
In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin?Alan W Carter
Journal of Diabetes Science and Technology|July 7, 2016
If PBMs Guard Access to Drugs, Then Quis Custodiet Ipsos Custodies? (Who Will Guard the Guardians?)Alan W Carter, Lutz Heinemann
Journal of Diabetes Science and Technology|December 23, 2017
Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply ChainAlan W Carter, Lutz Heinemann
Journal of Diabetes Science and Technology|May 24, 2018
In Response to Letters to the Editor From the American Diabetes Association and Eli Lilly in Regard to: Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply ChainAlan W Carter, Lutz Heinemann
Diabetes Technology & Therapeutics|September 9, 2017
Will Biosimilar Insulins Be Cheaper?Lutz Heinemann, Alan W Carter
Journal of Diabetes Science and Technology|March 19, 2016
Quality Control of Insulins and Biosimilar Insulins: What Do We Know?Alan W Carter, Lutz Heinemann, David C Klonoff, et al.
Pageof 2